Research programme: infected burns therapeutics - Creative Antibiotics

Drug Profile

Research programme: infected burns therapeutics - Creative Antibiotics

Alternative Names: INP 1750/1855; INP 341

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innate Pharmaceuticals AB
  • Developer Creative Antibiotics
  • Class
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections

Highest Development Phases

  • No development reported Pseudomonal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pseudomonal-infections in Sweden
  • 27 Oct 2011 Creative Antibiotics and AMRI collaborate to discover and develop antibiotics inhibiting T3SS virulence mechanism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top